BUZZ-Wave Life Sciences shares surge as its weight-loss drug enters combination therapy trial

September 23 - ** Drug developer Wave Life Sciences (WVE.O) saw its stock price rise 1.4% in pre-market trading to $4.41

** The company has started a mid-stage clinical trial combining its experimental weight loss drug WVE-007 with pharmaceutical company Eli Lilly's (LLY.N) once-weekly weight loss and diabetes injection tirzepatide

** WVE-007 is an RNA-based therapeutic drug designed to promote fat reduction while preserving muscle mass, with dosing required only once or twice a year

** The trial will target patients with obesity and type 2 diabetes, testing WVE-007 at 240 mg and 400 mg doses

** In animal studies, combination use of WVE-007 and GLP-1 drugs resulted in twice the weight loss compared to using GLP-1 therapy alone — WVE

** The company still plans to launch another clinical trial in the second half of 2026 to verify whether WVE-007 can suppress weight rebound after patients stop using incretin-based drugs

** As of the previous trading day close, WVE has fallen 74.4% so far this year

(To facilitate non-native English speakers, Reuters has its reports automatically translated into several other languages. Since automated translation may contain errors or lack needed context, Reuters does not guarantee the accuracy of the translated text, which is provided solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses arising from the use of the automated translation function.)